Table 1.
Clinical and demographic features of MS patients and healthy controls.
| SPMS patients (untreated) N=10 |
SPMS patients (treated with Siponimod) N=7 |
HC N=6 |
P value | |
|---|---|---|---|---|
| Age, years (Median,IQR) | 53 (41.5–63.5) | 54.0 (45.0–55.0) | 47.5 (46.8–49.5) | 0.675 |
| Sex (F/M) (%) |
4/10 (40.0) | 6/7 (85.7) | 3/6 (50.0) | 0.082 |
| Disease duration, years (Median,IQR) | 16.5 (11.8–19.5) | 20.0 (16.0–26.0) | – | 0.133 |
| Progressive phase duration, years (Median,IQR) | 6.3 (3.8–9.5) | 4.0 (3.0–7.0) | – | 0.270 |
| EDSS, value (Median,IQR) | 6.0 (5.5–6.5) | 4.5 (4.0–6.5) | – | 0.109 |
| OCB (yes/N tot) (%) |
9/10 (90) | 7/7 (100) | – | 0.588 |
| MRI activity (yes/N tot) (%) |
0/10 (0) | 0/7 (100) | – | – |
SPMS, secondary progressive multiple sclerosis; HC, healthy controls; IQR, interquartile range; F, female; M, male; EDSS, Expanded Disability Status Scale; OCB, oligoclonal bands; MRI, magnetic resonance imaging. Statistical analyses were assessed using Mann-Whitney for 2 independent samples, and Kruskall-Wallis for 3 independent samples.